Jim Breyer: Breyer Capital leads Pathway Labs funding for multi-condition AI heart diagnostics

Jim Breyer: Breyer Capital leads Pathway Labs funding for multi-condition AI heart diagnostics
Breyer backs Pathway Labs AI system

Pathway Labs has secured its first institutional investment, led by Breyer Capital, to advance its EchoNext system, an artificial intelligence platform that detects structural heart disease using standard ECG data. Pathway Labs also achieved a milestone by receiving the first FDA clearance for a multi-condition AI system in U.S. cardiology. Cardiovascular disease remains a leading health issue globally, underscoring the significance of innovations such as EchoNext.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.